Rabbit haemorrhagic disease, caused by rabbit hemorrhagic disease virus (RHDV), results in the death of millions of adult rabbits worldwide, with a mortality rate that exceeds 90 %. The sole capsid protein, VP60, is divided into shell (S) and protruding (P) domains, and the more exposed P domain likely contains determinants for cell attachment and antigenic diversity. Nine mAbs against VP60 were screened and identified. To map antigenic epitopes, a set of partially overlapping and consecutive truncated proteins spanning VP60 were expressed. Previous studies demonstrated that native viral particles and virus-like particles (VLPs) of RHDV specifically bound to synthetic blood group H type 2 oligosaccharides. We established an oligosaccharide-based assay to analyse the binding of VP60 and epitopes to histo-blood group antigens (HBGAs). Results showed VP60 and its epitopes (aa 326-331 and 338-342) in the P2 subdomain could significantly bind to blood group H type 2. Furthermore, mAbs 1B8 and 5H3 could block RHDV VLP binding to synthetic H type 2. Collectively, these two epitopes might play a key role in the antigenic structure of VP60 and interaction of RHDV and HBGA.
INTRODUCTION
Rabbit hemorrhagic disease virus (RHDV), a positive-sense single-stranded RNA virus in the genus Lagovirus of the family Caliciviridae, is the causative agent of rabbit haemorrhagic disease (RHD), which is characterized by high morbidity and high mortality in wild and domestic adult rabbits (Oryctolagus cuniculus) (Abrantes et al., 2012; Meyers et al., 1991a; Xu & Chen, 1989) . The genome of RHDV is 7.5 kb in length and contains two ORFs: ORF1 and ORF2. The former encodes a polyprotein precursor, which in its final form is cleaved into the 60 kDa major capsid protein (VP60), and several non-structural proteins (König et al., 1998; Meyers et al., 1991b Meyers et al., , 2000 . ORF2 encodes VP10, a basic protein present in virions in small amounts (Thiel & König, 1999) .
The main target of the host immune defence against RHDV is the capsid protein VP60, which is composed of the N-terminal arm, the shell (S) and the protruding (P) domains. The latter consists of subdomains P1 (aa 238-286, 450-466, 484-579) and P2 (aa 287-449 and 467-483) (Wang et al., 2013) . The subdomain P2, located at the most exposed region of the capsid, is recognized and targeted by host antibodies (Bárcena et al., 2004; Capucci et al., 1995; Martínez-Torrecuadrada et al., 1998) , and might also contain determinants for cell attachment and antigenic diversity of RHDV. Wang et al. (2013) found a flexible loop (aa 304-314) containing an important epitope in the P2 subdomain by analysis of the crystal structures of the S and P domains of VP60 at 2.0 Å resolution. This flexible loop contributes to host-virus interaction and is a major neutralization site that could induce an effective host immune response. The antigenicity of the VP60 protein has also been reported by other research groups (Laurent et al., 1997 (Laurent et al., , 2002 Martínez-Torrecuadrada et al., 1998) . However, research regarding epitopes on the P domain of VP60 is lacking, and the significance of these epitopes regarding immune response is unknown.
Histo-blood group antigens (HBGAs), which act as attachment factors for RHDV, are important for virus infection and might initiate the viral replication cycle (Nyström et al., 2011) . Native viral particles of RHDV as well as virus-like particles (VLPs) isolated from recombinant viral capsid proteins specifically bind to synthetic B, A and H type 2 blood group oligosaccharides (Nyström et al., 2011; Ruvoën-Clouet et al., 2000) . However, little is known regarding the interactions of RHDV and HBGA. Thus, it is necessary to discover the essential domains for HBGA receptor binding to the virus and further explore the interactions of RHDV and HBGA. The subdomain P2, located at the most exposed region of the capsid, contains antibody epitopes as well as the HBGA binding pocket. Multiple studies have identified specific residues within the norovirus P2 subdomain that are important for antibody and HBGA interactions (Chakravarty et al., 2005; Debbink et al., 2012; Kinnear & Linde, 2010; Rohayem et al., 2010) . Binding of HBGA to RHDV likely resembles binding to similar sites in norovirus. Unfortunately, the relationship between antibody and HBGA in RHDV remains unclear.
In this study, we obtained nine mAbs directed against the VP60 protein, and further identified its antigenic epitopes. We then established oligosaccharide-based assays to analyse the binding of full-length and truncated VP60 proteins to HBGA. We found that two epitopes bound to blood group H type 2 oligosaccharides. Our results suggest that these epitopes are important for HBGA binding and antibody response.
RESULTS

Preparation and identification of mAbs
Electron microscopy analysis showed expressed VP60 selfassembling into VLPs of approximately 40 nm diameter (Fig. 1a) . The RHDV VLPs were morphologically identical to native RHDV (Fig. 1a) .
After a series of screens, we obtained nine mAbs against the VP60 protein. The mAbs were identified as 1B8, 1D4, 3D11, 3F7, 4C2, 4G2, 5G2, 5H3 and 6B2. All mAbs recognized RHDV VLPs and native RHDV by Western blot analysis, as demonstrated by the presence of specific bands at *60 kDa (Fig. 1b) . All mAbs reacting with lysate of Spodoptera frugiperda cells (Sf9 cells) infected with WT Autographa californica nuclear polyhedrosis virus (rAc-WT) as a control did not result in specific bands.
Sf9 cells infected with rAc-VP60 or rAc-WT were tested against all mAbs. Cells infected with rAc-VP60 displayed specific green fluorescence; cells infected with rAc-WT did not show any fluorescence (Fig. 1c) . These results indicated all mAbs could specifically recognize VP60 protein.
Analysis using a mouse monoclonal antibody isotyping ELISA kit revealed that 1D4 and 3F7 belonged to the IgG1-l subtype, while the remaining mAbs were IgG1-k.
Precise localization of epitopes
The truncated VP60 proteins were schematized and are listed in Fig. 2 . All proteins were expressed fused with His-Tag and reacted with all mAbs. The test results were also summarized in Fig. 2 : mAbs 1B8, 3D11, 4C2 and 4C2 recognized aa 330-350 of VP60; mAbs 1D4, 3F7, 5G2 and 6B2 recognized aa 559-579 of VP60; and the epitope recognized by mAb 5H3 is located within aa 520-540 of VP60.
To locate the minimal motif of each epitope, a series of truncated proteins were designed and expressed. The truncated proteins identified as C1-C13 were used for mapping the 5H3 epitope (Table S1 , available in the online Supplementary Material), S1-S11 for mAb 1B8 (Table S2) and F1-F11 for mAb 1D4 (Table S3 ). All truncated proteins were expressed at their expected sizes as visualized by SDS-PAGE (Fig. 3a-c) . The interaction of truncated proteins with corresponding mAbs was detected by Western blot. mAb 5H3 reacted with all fragments (C1-C7 and C9-C10) containing the amino acids N 326 PISQV 331 but not with the proteins where any one of these six amino acids was deleted (C8, C11, C12, C13) (Fig. 3a) . Hence, N 326 PISQV 331 was essential for the mAb 5H3 epitope. Similarly, mAb 1B8 recognized S1, S2, S3, S7 and S8 but did not bind to S4, S5, S6, S9, S10 and S11 (Fig. 3b) . Therefore, D
338
MSFV
342 was identified as the minimal sequence of this epitope. The proteins F1, F2, F3, F7 and F8 were recognized by 1D4, while this mAb did not react with the remaining samples (Fig. 3c) . Consequently, K 562 STLVFNL 569 was identified as the minimal motif of the mAb 1D4 epitope.
Alignment of epitope sequences
We aligned the epitope sequences of 21 RHDV strains encompassing RHDV genogroups 1-6 as well as the RHDV2 (RHDVb) variant, to investigate conservation of the epitopes. The epitope D 338 MSFV 342 , recognized by mAb 1B8, was completely conserved among all the RHDV isolates (Fig. 4) . The epitope N 326 PISQV 331 was highly conserved among all RHDV strains, except for a V331RI331 substitution in RHDV2 strains (Fig. 4) . The K 562 STLVFNL 569 epitope was relatively conserved among the RHDV G1-G6 strains, but it was variable in RHDV2 strains with K562RT562 and F567RY567 (Fig. 4) .
Binding of VLPs and truncated VP60 proteins to HBGA
When VP60 VLPs were titrated for binding to oligosaccharide by ELISA, a linear relationship between binding and VLP concentration was observed between 0.25 and 4.0 mg ml 21 (Fig. 5a ). The control groups showed no oligosaccharide binding. These results indicated that VP60 could specifically bind to oligosaccharide. A final concentration of 2.0 mg ml 21 was used in subsequent binding assays.
The truncated proteins C1, C7 and C8 could specifically react with the polyacrylamide (PAA)-biotin-conjugated H type 2 trisaccharides ( Fig. 5b) , as detected by mAb 5H3. Compared with the control group, the reaction values of C1, C7 and C8 had statistical significance (Pv0.01). Similar results were found for the truncated proteins S1, S3 and S8, detected by mAb 1B8 (Pv0.01) (Fig. 5c ). However, the OD 450 values measured for binding to truncated proteins F1, F3 and F8 did not significantly differ from those of the PBS group (Pw0.05) (Fig. 5d) . Hence, F1, F3 and F8 did not react with HBGA. The OD 450 values measured for the VP60 positive control revealed significant differences when compared with PBS (Pv0.01) ( Fig. 5b-d) .
RHDV mAb blocking of VLP and truncated VP60 protein binding to HBGA
We performed experiments to test the blocking ability of anti-VP60 mAbs in our oligosaccharide binding assays. Blocking activity was scored based on levels of reduction of the OD 450 values for wells with blocking mAbs compared those for wells without. The OD 450 values of wells containing blocking mAbs significantly differed from those of the negative control group without mAbs (Pv0.01) (Fig. 6a,c) . mAb 5H3 could strongly block binding of truncated proteins C1, C7 and C8 to oligosaccharide conjugates, with a blocking rate of almost 100 % (Fig. 6a, b) . Furthermore, this mAb partially blocked the binding of the VP60 VLPs to oligosaccharide conjugates by *70 % (Fig. 6b) .
Likewise, mAb 1B8 could also completely block S1, S3 and S8 binding to oligosaccharide conjugates (Fig. 6c, d ). However, it only blocked *50 % of the binding of the VP60 VLPs to oligosaccharide (Fig. 6d) . Thus, we concluded that mAbs 1B8 and 5H3 could block RHDV binding to HBGA.
DISCUSSION
The capsid protein (VP60) of RHDV is important for viral diagnosis and vaccine design. The immune response induced by VP60 protein expressed in insect cells provided complete protection against lethal RHDV challenge, and serological immune response against RHDV has also been shown to play an important role in protection (Castañó n et al., 1999; Laurent et al., 1994; Parra & Prieto, 1990) . Furthermore, IgG, present in the serum of recovering rabbits, increases over time and can persist for months to protect against RHDV (Ferreira et al., 2005) . Thus, there is considerable interest in understanding the factors that contribute to the development of antibody response following RHDV infection. In this study, we prepared nine mAbs specific for VP60 and analysed the distribution of their antigenic epitopes. We found that all mAbs belonged to the IgG subclass, demonstrating the potential Interaction of novel RHDV B-cell epitopes with HBGA application of these mAbs in the diagnosis of RHDV. After considerable analysis, three epitopes were found to be located within the P subdomain of VP60. One epitope (aa 562-569) in the P1 subdomain was recognized by four mAbs (1D4, 6B2, 3F7 and 5G2). Two epitopes (aa 326-331 and 338-342) in the P2 subdomain were recognized by one and four mAbs, respectively. Based on the published structure of VP60, the epitopes at aa 326-331 and 338-342 are located within loop 2 of the P2 subdomain, which is located on the outer surface of the RHDV capsomere and might contribute to HBGA binding .
RHDV strains are usually divided into two genotypes, termed RHDV and RHDVb (Dalton et al., 2012) . The subclusters in the distinct RHDV groups have been termed genogroups 1-6 (G1-G6) (Le Gall-Reculé et al., 2003 Le Gall et al., 1998; Nyström et al., 2011; Wang et al., 2012) . The G6 cluster is also referred to as RHDVa (Capucci et al., 1998) , while the RHDVb branch is also identified as RHDV2 (Dalton et al., 2012; Le Gall-Reculé et al., 2013; Puggioni et al., 2013 In order to confirm whether these epitopes contribute to HBGA binding, we performed synthetic oligosaccharidebased binding assays and mAb blocking assays. Based on reports of RHDV binding to HBGA (Nyström et al., 2011), we selected H type 2 HBGA for use in our assay. Our results showed that two epitopes (aa 326-331 and 338-342) in the P2 subdomain could significantly bind to HBGA. However, the epitope located in the P1 subdomain could not bind to HBGA, which is consistent with a recent report (Wang et al., 2013) . To further investigate the ramifications of this, two mAbs directed against the P2 subdomain epitopes were used to block the binding of VLPs and truncated VP60 proteins to HBGA. The 1B8 and 5H3 mAbs almost completely blocked the interaction of the truncated VP60 proteins and HBGA, but only partially blocked VP60 binding to HBGA. RHDV binds to the HBGA H type 2, A type 2 and B type 2 oligosaccharides (Nyström et al., 2011; Ruvoën-Clouet et al., 2000) . The virus first encounters these proteins when infecting the host and uses them for viral entry (Ruvoën-Clouet et al., 2000) . mAbs 1B8 and 5H3 could block VP60 VLP binding to synthetic H type 2. In order to determine whether the presence of carbohydrate-blocking antibody is indicative of a protective antibody response, we will collect and evaluate the antisera from RHDVinfected rabbits and from rabbits inoculated with RHDV vaccine in future research. Future studies will be needed to fully understand the significance of receptor-blocking antibody in RHDV immunity.
In this study, we identified for the first time, we believe, two epitopes that act as HBGA binding sites on the RHDVa P domain. New research using X-ray crystallography indicates that the HBGA binding site on the RHDVb capsid-protruding domain (P domain) comprises Asp472, Asn474 and Ser479 (Leuthold et al., 2015) . Although they share 84 % amino acid identity, structural comparisons of the RHDVa and RHDVb P domains showed that the P1 subdomain helices and the P2 subdomain extended loops were slightly shifted (Leuthold et al., 2015) . Whether the HBGA binding site on the RHDVb is also a binding site on RHDVa awaits investigation by peptide binding assay. Taken together, these new findings extend our understanding of RHDV-HBGA interactions. These results may also help to elucidate the relationship between antigenicity and HBGA binding sites in RHDV infections. The RHDV VLPs were expressed and purified according to previously described methods (Chen et al., 2014) . The particles were partially purified by sucrose gradient centrifugation and identified by electron microscopy. The concentrations of the VLP preparations were determined with a bicinchoninic acid protein assay kit (Pierce).
mAbs were screened according to a standard hybridoma technique Khawsuk et al., 2002) . Female BALB/c mice, 6-8 weeks of age, were immunized subcutaneously and intraperitoneally by multipoint injection with 100 mg of purified VLPs. The immunization routes were the same as previously described (Song et al., 2012) . The fused hybridoma clones were screened and identified by indirect ELISA for mAbs that demonstrated strong reactivity with the VP60 VLPs and no reactivity with proteins from Sf9 cells infected with rAc-WT.
Western blot. The purified VLPs and the native RHDV were separated by 12 % SDS-PAGE and transferred to nitrocellulose membranes (Pall). After blocking overnight with PBS-5 % (w/v) skimmed milk at 4 uC, the membranes were incubated with each mAb at a 1 : 1000 dilution at 37 uC for 1 h, followed by incubation with goat anti-mouse IgG-HRP. At the end of each step, the membranes were washed three times with PBS-0.05 % Tween 20 (v/v)(PBS-T). Signals were captured and measured using an ECL Western blotting Substrate (Pierce).
Indirect immunofluorescence assay. Sf 9 cells infected with rAc-VP60 and rAc-WT for 36 h in 24-well culture plates were rinsed with PBS and fixed with cold 95 % ethanol for 10 min at 4 uC. After washing three times with PBS-T, cells were incubated with the mAbs (1 : 100 diluted in PBS-T) for 1 h at 37 uC. Secondary dye-coupled antibodies (FITC-conjugated goat anti-mouse IgG) were added at 1 : 100 dilution and incubated at 37 uC for 1 h. After rinsing five times, the plates were examined under a Zeiss fluorescence microscope.
Precise localization of epitopes. To map antigenic epitopes recognized by mAbs, a series of primers were designed and synthesized to amply the truncated fragments of VP60 (Fig. 2) . A series of PCR products were subcloned into pET-32a digested by Eco RI and Xho I restriction endonucleases. The recombinant truncated proteins were expressed by IPTG induction and used to determine the epitopes recognized by mAbs using the Western blot method described above.
Following these experiments, we could determine the epitopes within 20 amino acids. To obtain the minimal motifs of epitopes, the precise analysis was carried out by sequential deletion of the terminal amino acid residues encoding the polypeptides C1-C13, S1-S11 and F1-F11, which are listed in Tables S1-S3, respectively. The consecutive complementary oligonucleotides coding for the truncated proteins were synthesized and annealed with the sticky ends of Eco RI and Xho I restriction endonuclease sites formed at the termini of the doublestranded oligonucleotides. The oligonucleotides were then cloned into pET-32a digested by Eco RI and Xho I to obtain a series of recombinant plasmids. The expression of the fusion peptides and Western blot detection were performed according to the descriptions above. Alignment of epitope sequences. The names and accession numbers of strains from different virus subtypes are listed in Table S4 . The amino acid sequences of VP60 were downloaded from GenBank. Multiple alignments of amino acid sequences of epitopes were created using DNASTAR MEGALIGN software.
Binding assay of the VLPs on synthetic carbohydrates. The synthetic carbohydrate binding assays were performed as previously described (Farkas et al., 2010; Nyström et al., 2011; Ruvoën-Clouet et al., 2000; Uusi-Kerttula et al., 2014) . The PAA-biotin conjugated H type 2 trisaccharides (5 mg ml 21 ; GlycoTech) were coated on a Pierce NeutrAvidin high binding capacity coated 96-well plate (Thermo) overnight at 4 uC. After blocking with PBS-5 % (w/v) skimmed milk, VP60 VLPs at 0.25-4.0 mg ml 21 in PBS were added to detect VP60 VLP binding to synthetic carbohydrates, and incubated for 1 h at 4 uC. The bound VLPs were then detected with mAb 1B8 (at dilution of 1 : 1000). Next, HRP-conjugated goat anti-mouse IgG antibodies were added for 1 h at 37 uC. After each step, the plates were washed five times with PBS. The enzyme signals were detected using TMB (3,39,5,59-tetramethylbenzidine) reagent and then read at 450 nm in an automatic ELISA plate reader. Sf9 cells infected with rAc-WT and PBS were used as controls that received the same treatment as did the VP60 VLPs.
Synthetic oligosaccharide-based binding assays of truncated VP60 proteins. Binding of truncated VP60 proteins to HBGA was tested with Pierce NeutrAvidin high binding capacity coated 96-well plates coated with PAA-biotin-conjugated H type 2 trisaccharides (5 mg ml 21 ). After blocking, the truncated proteins and baculovirusexpressed RHDV VLPs were added at a concentration of 2 mg ml 21 in PBS. The truncated proteins S1, S3 and S8 were detected by mAbs 1B8; the truncated proteins F1, F3 and F8 were detected by mAb 1D4; VLPs to the PAA-biotin-conjugated H type 2 trisaccharides was used as a positive control, while binding to PBS was used as a negative control. **Significant difference between groups (P,0.01).
and the truncated proteins C1, C7 and C8 were detected by mAb 5H3 (all diluted 1 : 1000). Baculovirus-expressed RHDV VLPs were also tested with all mAbs as a positive control. PAA-biotinconjugated H type 2 trisaccharide-coated wells without antigens served as negative controls. Triplicate wells were used for each sample. For each step, the plates were incubated for 1 h at 37 uC and washed five times with PBS-T. The following detection steps were the same as described above. Samples were analysed in at least two separate experiments.
RHDV mAbs blocking of HBGA binding to VLPs and the truncated VP60 proteins. The same conditions of oligosaccharide binding assays described above were used. The ability of the mAbs to block the binding of VLPs and the truncated VP60 proteins to H type 2 carbohydrates was tested using specific mAbs (1 : 1000). First, RHDV VLPs and the truncated VP60 proteins were pre-incubated with specific mAbs for 1 h at 37 uC before transfer to the oligosaccharide-coated plate. Ascites from mice inoculated with SP2/0 myeloma cells and PBS were used as a negative control and a blank control, respectively.
The VLPs and the truncated VP60 proteins (in the presence or absence of mAb) were added to carbohydrate-coated plates and incubated for 2 h. After washing, mAbs at a dilution of 1 : 1000 were added into corresponding wells, followed by incubation with HRP-conjugated goat anti-mouse IgG. The levels (%) of blocking were calculated from the difference in OD 450 values between wells with pre-incubation with mAbs and with ascites from mice inoculated with SP2/0 myeloma cells. Samples were analysed in at least two separate experiments. 
